Skip to main content
NCBI home page
Oncology Letters logoLink to Oncology Letters
. 2018 Nov 13;17(1):1042–1052. doi: 10.3892/ol.2018.9693

Ex situ hepatectomy and liver autotransplantation for a treating giant solitary fibrous tumor: A case report

Zhongquan Sun 1,2,3,*, Yuan Ding 1,2,3,*, Yuancong Jiang 1,2,3,*, Qiyi Zhang 1,2,3, Zhiwei Li 1,2,3, Jie Xiang 1,2,3, Jixuan Duan 1,2,3, Sheng Yan 1,2,3,✉, Weilin Wang 1,2,3,✉
PMCID: PMC6312964  PMID: 30655864

Abstract

A solitary fibrous tumor (SFT) is a rare mesenchymal tumor. Ex situ hepatectomy and liver autotransplantation are novel methods for the treatment of complicated liver tumors, for example, those involving vascular structures, including the inferior vena cava, which are unresectable by conventional approaches. The present study describes a rare case of a massive hepatic SFT in a 32-year-old female who underwent ex situ hepatectomy and liver autotransplantation to achieve a radical resection. The surgery was without complications. Post-operative histopathological and immunohistochemical examinations revealed an SFT of the liver. The patient was discharged 29 days after the surgery with fully recovered liver function. The routine check-up 3 months after surgery indicated normal liver function and no evidence of recurrence. Additionally, an exhaustive review of available literature was performed to provide a complete overview of the current status of SFTs. In summary, the present study found that ex situ hepatectomy and liver autotransplantation are suitable surgical techniques for treating a giant SFT, as well as other liver neoplasms that are considered unresectable by conventional surgery.

Keywords: solitary fibrous tumors, ex situ hepatectomy, liver autotransplantation, prognosis

Introduction

A solitary fibrous tumor (SFT) is a rare mesenchymal tumor, which can be found in different locations within the human body (1). SFTs were first reported in the pleura and subsequently in the peritoneum, thymus, orbit, pericardium, meninges, spinal cord, and the parotid and thyroid glands (2). A tumor of this type in the liver is an extremely rare occurrence. The majority of SFTs are considered benign, while <20% are reported to be malignant and are accompanied by tumor invasion and metastasis (3). Surgical resection is the main approach for SFT treatment. Nevertheless, in certain cases where vascular structures are involved, conventional surgery may not be practical.

Ex situ hepatectomy and liver autotransplantation are novel methods for treating complicated liver tumors that are unresectable by conventional approaches, including liver transplantation, vascular reconstruction, organ perfusion, extended hepatic resection and hemodynamic management, which are considered to be some of the most complicated, difficult and risky types of surgeries. In this maneuver, the whole liver is removed and perfused with cold preservation solution. The tumor is resected ex situ on the operating table and the remaining liver is orthotopically implanted. The ex situ liver resection was first described by Pichlmayr et al (4) as a novel surgical procedure to treat a bilateral liver leiomyosarcoma. To date, only a few cases of ex situ hepatectomy and liver autotransplantation have been described worldwide (5,6). Furthermore, to the best of our knowledge, there are no reports on adopting ex situ hepatectomy and liver autotransplantation as an approach for treating hepatic SFTs. The present case study reports the first case of a giant SFT involving the inferior vena cava (IVC) of the liver in a 32-year-old female who was treated with ex situ hepatectomy and liver autotransplantation.

Case report

A 32-year-old female suffering from repeated abdominal distension for 3 years was found to have an oversized mass in the right hepatic lobe using a B-scan ultrasound, and was admitted on July 7, 2017 to the Outpatient Department of the First Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). A physical examination revealed a large mass in the right hypochondrium, causing local discomfort. No aberration was observed regarding the medical history of the patient. In addition, no elevation of tumor markers, including α-fetoprotein (AFP; ARCHITECT AFP Reagent kit; cat. no. 3P36-30; Abbott Pharmaceutical Co., Ltd., Lake Bluff, IL, USA), carcinoembryonic antigen (CEA; ARCHITECT CEA Reagent kit; cat. no. 7K68-32; Abbott Pharmaceutical Co., Ltd.), cancer antigens (CA) 125 (ARCHITECT CA 125 II Reagent kit; cat. no. 2K45-35; Abbott Pharmaceutical Co., Ltd.) and 19-9 (ARCHITECT CA 19-9 XR Reagent kit; cat. no. 2K91-38; Abbott Pharmaceutical Co., Ltd.), was observed, as detected using immunofluorescence assays, according to the manufacturers protocols. Hepatitis virus markers were all negative, as detected using an immunofluorescence assay (ARCHITECT Reagent kits; cat. nos. 6C36-44, 8L44-30, 6C34-35, 6C32-20 and 7C18-34; Abbott Pharmaceutical Co., Ltd.), according to the manufacturers protocol. The patient underwent an enhanced abdominal computed tomography (CT) scan, which revealed a giant, hypodense, heterogeneous, cystic-solid lesion (20.0×16.0 cm), with irregular contrast enhancement, causing compression of neighboring structures. Dilation of the intrahepatic biliary ducts was also noted (Fig. 1). A CT arteriography scan showed that the mass was supplied with blood by the left and right hepatic arteries. The right, middle and left hepatic veins were compressed by the mass and there was indication of a filling defect in the IVC. A magnetic resonance imaging scan was also performed, revealing an oversized, heterogeneous liver mass (21.2×19.7 cm). A heterogeneous high signal in the T2-weighted image and a slightly low signal in the T1-weighted image were observed. All results indicated that the lesion was malignant and a mesenchymal tumor was suspected.

Figure 1.

Figure 1.

Open in a new tab

Abdominal computed tomography scan prior to surgery and gross examination of the specimen. Abdominal computed tomography scans [(A) plain, (B) arterial and (C) portal phase] revealed a large, hypodense, heterogeneous, cystic-solid lesion measuring 20.0×16.0 cm, with irregular contrast enhancement, causing compression of the neighboring structures. (D) The resected specimen was well-delimited and measuring ~19×19.5×14 cm, with a grayish-white interlaced appearance of the section plane.

In view of the young age of the patient, an ex situ hepatectomy and liver autotransplantation were performed on October 17, 2017. During the surgery, the second hepatic portal was difficult to expose and the sternum was therefore removed with the assistance of a cardiothoracic expert. An intra-operative frozen section examination indicated the proliferation of fibrotic tissue, and the tumor was considered to be benign. Consequently, the tumor was resected on the bench. A 26-mm artificial blood vessel was utilized to establish an end-to-side portocaval shunt during the anhepatic period and the liver remnant was autotransplanted in a piggyback fashion. The surgery was without complications and lasted for 18 h, with an anhepatic period of 5 h.

The resected specimen was well-delimited and measured 19.0×19.5×14.0 cm in size and 3.964 kg in weight. The tumor presented with a grayish-white interlaced appearance in the section plane, and was comprised of spindle-shaped cells infiltrated with lymphocytes, plasmocytes and mastocytes (Fig. 2). The immunohistochemical (IHC) examination was performed on paraffin-embedded specimens fixed in 4% buffered neutral formalin at 37°C for 24 h. Paraffin-embedded sections (3 µm) were deparaffinized and and endogenous peroxidase was inactivated with 15% H2O2-Methanol for 5 min at room temperature. The sections were then incubated with primary antibodies at 37°C for 30 min, according to the manufacturers protocols. Subsequently, the sections were incubated with Dako REALREEnVision Detection system, Peroxidase/DAB, Rabbit/Mouse (cat. no. K5007; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) for 30 min at room temperature. Results revealed that the sections were positive for cluster of differentiation 117 (CD117; cat. no. 790-2951; dilution 1:100; Roche Diagnostics, Basel, Switzerland), CD34 (cat. no. M-0117; dilution 1:50; Shanghai Changdao Biotechnology Co., Ltd., Shanghai, China) and Caldesmon (cat. no. ZA-0535; dilution 1:100; OriGene Technologies, Inc., Beijing, China). In addition focal expression of smooth muscle actin (cat. no. ZM-0003; dilution 1:100; OriGene Technologies, Inc.) and progestrone receptor (cat. no. NCL-L-PGR-312; dilution 1:300; Leica Biosystems, Ltd., Milton Keynes, UK) expression was detected. However, sections were negative for S-100 protein (cat. no. ZA-0225; dilution 1:200; OriGene Technologies, Inc.), desmin (cat. no. ZM-0091; dilution 1:100; OriGene Technologies, Inc.), deletions of G-rich-1 (cat. no. ZM-0371; dilution 1:200; Zhongshanjinqiao Bio-Reagent Company), cytokeratin (cat. no. M-0349; dilution 1:100; Shanghai Changdao Biotechnology Co., Ltd.), β-catenin (cat. no. ZM-0442; dilution 1:100; OriGene Technologies, Inc.), anaplastic lymphoma kinase (cat. no. ALK-L-CE-H; dilution 1:150; Leica Biosystems, Ltd.), estrogen receptor (cat. no. NCL-L-ER-6F11; dilution 1:100; Leica Biosystems, Ltd.), epithelial membrane antigen (cat. no. ZM-0095; dilution 1:200; Zhongshanjinqiao Bio-Reagent Company), wilms tumor type 1 (cat. no. ZM-0269; dilution 1:100; Zhongshanjinqiao Bio-Reagent Company) and CD10 (cat. no. NCL-L-CD10-270; dilution 1:100; Leica Biosystems, Ltd.). The sections were evaluated under a light microscope at ×200 magnification. The mean proliferative index was 5% in the hypercellular areas, as determined by detection of antigen KI-67 (Ki-67; cat. no. ZM-0166; dilution 1:100; Zhongshanjinqiao Bio-Reagent Company). The Ki-67 proliferative index was examined under a light microscope (BX53; Olympus Corporation, Tokyo, Japan), and was evaluated by experienced pathologists. A total of 500 tumor cells were counted both at the center and at the periphery of the tumor. The examination was repeated at least twice and the mean Ki-67 proliferative index was calculated. At least 10 mm of the margins of the resected specimen were tumor-free. Based on the pathological and IHC characteristics, the lesion was identified as an SFT.

Figure 2.

Figure 2.

Open in a new tab

Histological examination showed that the tissues consisted of spindle-shaped cells that were infiltrated with lymphocytes, plasmocytes and mastocytes. The images are of hematoxylin and eosin staining at (A) ×50, (B) ×100, (C) ×200 and (D) ×400 magnification.

On post-operative day 9, the patient underwent pleurocentesis and received drainage tubes due to moderate right pleural effusion, which were successfully removed 16 days later. The patient recovered fully and was discharged on post-operative day 29. At the 1- and 3-month follow-ups, the patient had normal liver function and there was no evidence of recurrence. Future follow-up will be performed every 6 months.

Discussion

SFTs are mesenchymal neoplasms that typically occur in the thoracic or pleural cavities. The SFTs found in the liver may derive from the intra-hepatic connective tissue, for example Glisson's capsule or conjunctive tissue, which are rare types of liver neoplasm (7). A search of the English literature on ‘Solitary Fibrous Tumour of the Liver’ was conducted on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) and Google (https://www.google.com/). All published English articles, case reports and literature reviews, and their reference lists, were reviewed. The results indicated that only 88 cases of SFTs of the liver have been reported since 1958 (7–71). The main characteristics of these cases are listed in Table I. The mean age of onset was 57.1 years (range, 16.0–87.0 years) and the lesion appeared more commonly in female patients (ratio 1.4:1), with a mean tumor diameter of 18.2 cm (range, 1.5–30.0 cm). The median follow-up time for these cases was 13.5 months. The prolonged course and biological features of SFTs resulted in a relatively late age of onset and large lesion size. The patient in the present study was a 32-year-old female with a single lesion measuring ~19.0 cm; these characteristics were consistent with the cases listed in Table I.

Table I.

Main characteristics of reported liver solitary fibrous tumor cases.

First author, year Age, years Sex Lobe Size, cm Hypo Treatment IHC Follow-up (Refs.)
Edmondson, 1958 16 F R 23×17 N Resection N/A 24 months (8)
N/A N/A R 5×5 N Resection N/A N/A
Nevius and Friedman, 1959 56 M R 15×15 Y Radiation N/A Succumbed after 2 days (9)
Ishak, 1976 62 M L 24 N Resection N/A N/A (10)
62 F L 23×20×13 N Resection N/A Succumbed during surgery
Kim and Damjanov, 1983 27 F L 27×23×15 N Resection N/A 6 months (11)
Kottke-Marchant et al, 1989 84 F L 15×9×8 N Resection V+ 29 months (12)
Kasano et al, 1991 39 F L 18×10×18 N Resection N/A 53 months (13)
Barnoud et al, 1996 50 M R 17×15×11 N Resection CD34+, V+ N/A (14)
Levine and Rose, 1997 57 M L 10×18×8 N Resection CD34+, V+ 38 months (15)
Guglielmi et al, 1998 61 F R 20×16×10 Y Resection CD34+, V+ 72 months (16)
Lecesne et al, 1998 69 F L N/A N Resection CD34+, V+ 12 months (17)
Bejarano et al, 1998 49 M L 17×12×10 N Resection CD34+, V+ 15 months (18)
Moran et al 1998 62 F N/A 23×20×13 N Resection CD34+, V+ N/A (19)
34 F N/A 2×0.5 N Nil N/A Incidental (autopsy)
57 F N/A 24×19×11 N Resection CD34+, V+ N/A
32 M N/A 12×9×7 N Resection CD34+, V+ N/A
68 F N/A 17×17 N Resection CD34+, V+ Succumbed after 2 days
83 F R 18 Y Resection CD34+, V+ Succumbed after 6 days
72 F L 9 N Resection CD34+, V+ 12 months
62 M L 24 N Resection CD34+, V+ N/A
50 F N/A 3×2×1.5 N Resection CD34+, V+ N/A
Fuksbrumer et al, 2000 40 F R 14–17 N Resection CD34+, V+, Bcl-2+ N/A (20)
71 F R 14–17 N Resection CD34+, V+, Bcl-2+ N/A
80 M R 14–17 N Nil CD34+, V+, Bcl-2+ N/A
Yilmaz et al, 2000 25 F R 32×30 N Resection V+ 6 months (21)
Lin et al, 2001 75 M R 21×20×18 Y Resection CD34+ 11 months (22)
Gold et al, 2002 N/A N/A N/A N/A N N/A N/A N/A (23)
N/A N/A N/A N/A N N/A N/A N/A
Neeff et al, 2004 63 F R 30×12×19 N Resection CD34+, V+ 6 months (24)
Chithriki et al, 2004 76 F R 20×15×16 Y Resection CD34+, Bcl-2+ 11 months (25)
Vennarecci et al, 2005 65 M R 30×28×14 N Resection CD34+, V+ 30 months (26)
Moser et al, 2005 73 F R 35×20×15 Y Resection CD34+, V+, Bcl-2+ N/A (27)
Ji et al, 2006 42 F R 6×5×5 Y Resection CD34+ N/A (28)
Lehmann et al, 2006 63 F R N/A N Resection CD34+ 96 months (7)
Nath et al, 2006 61 F R 21×14.5×30 N Resection CD34+, V+ 10 months (29)
Terkivatan et al, 2006 74 M L 24×21×15 N Resection CD34+, CD99+, V+, Bcl-2+ 12 months (30)
Chan et al, 2007 70 M R 27×24×12 Y Resection CD34+, CD99+, V+, Bcl-2+ 9 months (31)
Obuz et al, 2007 52 M L 10×11×12 N Resection CD34+, V+ 22 months (32)
Perini et al, 2008 40 F L N/A N Resection CD34+, V+ 49 months (33)
Weitz et al, 2007 N/A N/A N/A N/A N Resection N/A N/A (34)
N/A N/A N/A N/A N Nil N/A N/A
N/A N/A N/A N/A N Nil N/A N/A
Kandpal et al, 2008 45 F R N/A N Resection CD34+ N/A (35)
Fama et al, 2008 68 M R N/A Y Resection CD34+, V+ 25 months (36)
Korkolis et al, 2008 82 F L 18×15×8 N Resection CD34+, V+, Bcl-2+, desmin+ 21 months (37)
Chen et al, 2008 71 M R 8.7×5.5×8.5 N Resection CD34+, CD99+, Bcl-2+ 9 months (38)
El-Khouli et al, 2008 68 F L, R 15×10.5×13 N TACE CD34+, V+ N/A (39)
Hoshino et al, 2009 30 F R 6.7×4.5×4 N Nil CD34+, Bcl-2+ 6 months (40)
Novais et al, 2010 34 F R 25×23×13 N Resection CD34+, V+ 24 months (41)
Brochard et al, 2010 54 M R 17 N Resection CD34+, V+, desmin+, actin+ 72 months (42)
Haddad et al, 2010 62 M L N/A N Resection CD34+ N/A (43)
45 F R 7.4×5.9×5.4 N Resection CD34+, V+, Bcl-2+ N/A
Park et al, 2011 51 F L N/A N Resection N/A N/A (44)
Peng et al, 2011 24 F R 30×17×15 N Resection CD34+, V+, Bcl-2+ Succumbed after 16 months (45)
Sun et al, 2011 59 M L 9×7×6 N Resection CD34+, CD99+, V+, Bcl-2+ 24 months (46)
Patra et al, 2012 34 F L 14.5×10×8 N Resection CD34+, V+, Bcl-2+ 48 months (47)
Radunz et al, 2012 85 F L N/A Y Resection CD34+, Bcl-2+ N/A (48)
Belga et al, 2012 66 F R N/A N Resection CD34+ 30 months (49)
Morris et al, 2012 23 F R 27× 23.5×4 N Resection CD34+, V+, Bcl-2+ 10 months (50)
Beyer et al, 2012 46 M RLig 21×7 N HRT, chemo therapy, resection CD34+ 10 months (51)
Soussan et al, 2013 64 M L N/A N Resection CD34+, Bcl-2+ N/A (52)
Liu et al, 2013 42 M L 1.5×1×1 N Resection CD34+, Bcl-2+ N/A (53)
Jakob et al, 2013 62 F L N/A N Resection CD34+, CD99+, Bcl-2+ N/A (54)
Debs et al, 2014 65 M L N/A N Resection CD34+, CD99+, Bcl-2+ 12 months (55)
87 F R 14.6×12.3×17 N Nil N/A 10 months
Guray-Durak et al, 2013 38 F L 8×6×2 N Resection CD34+, CD99+, SMA+ N/A (56)
Vythianathan and Jim, 2013 78 M L 17×13 N Resection CD34+, CD99+, V+, Bcl-2+ N/A (57)
Song et al, 2014 49 M L, R 7.6×5×4.8 N Resection CD34+, V+, Bcl-2+ 3 months (58)
Texeira et al, 2014 68 F L 7.5×6.5×5.5 N Resection CD34+, V+ 28 months (59)
Du et al, 2015 55 F L 11×17×15 Y Resection CD34+, Bcl-2+ 60 months (60)
Beltran, 2015 58 M L 15×9×6 N Resection CD34+, V+ 36 months (61)
Bejarano-Gonzalez et al, 2015 79 F R 15 N TACE, resection CD34+, V+, Bcl-2+ 31 months (62)
Feng et al, 2015 51 M R 2.3×0.3 N Resection CD34+, Bcl-2+ 11 months (63)
49 M L 8.7 N Resection CD34+, V+, Bcl-2+ 17 months
51 F R 8.4 N Resection, adjuvant chemotherapy CD34+, V+, Bcl-2+ 31 months
52 F R 12 N Resection, MWA CD34+, V+ 37 months
Silvanto et al, 2015 65 M L 18 N Resection CD34+, CD99+, Bcl-2+ 16 months (64)
Kueht et al, 2015 40 M L 4.7×4×4 N Resection CD34+, CD99+, V+, Bcl-2+ N/A (65)
Maccio et al, 2015 74 F R 24×16 N Resection CD34+, V+, Bcl-2+, STAT6+ Succumbed after 15 months (66)
80 F R 19×15 N Chemotherapy CD34+, V+, Bcl-2+, STAT6+ Succumbed after 4 months
65 M R 3×2 N Chemotherapy CD34+, V+, Bcl-2+, STAT6+ Succumbed after 5 months
Makino et al, 2015 55 M R 8.6×6.3 N Resection CD34+, CD99+, Bcl-2+ 11 months (67)
Dey et al, 2016 56 F R 23×22×10 N Resection CD34+, V+, Bcl-2+ 6 months (68)
Degnan et al, 2016 39 M L 20×18×15 Y Resection CD34+, V+, Bcl-2+, STAT6+ 6 months (69)
Macak et al, 2016 64 N/A R 20×14.6×19 Y Resection, TACE NSE+, CD34+, V+, Bcl-2+, STAT6+ N/A (70)
Chen and Slater, 2017 61 M R 15×11.5×7.5 N Resection CD34+, CD99+, Bcl-2+ 74 months (71)
Present case 32 F L, R 19×19.6×14 N Ex situ hepatectomy and liver autotransplantation CD34+, CD117+, Caldesmon+, SMA+, PR+ 3 month −
Open in a new tab

Hypo, hypoglycemia; IHC, immunohistochemistry; N/A, not available; F, female; M, male; L, left; R, right; RLig, round ligament; TACE, transarterial chemoembolization; HRT, hormone replacement therapy; MWA, microwave ablation; CD, cluster of differentiation; V vimentin; Bcl-2, B-cell lymphoma 2; STAT6, signal transducer and activator of transcription 6; NSE, neuron specific enolase; SMA, smooth muscle actin; PR, progestrone receptor.

Due to the lack of overt or specific symptoms, patients with SFTs are usually diagnosed coincidentally during a check-up or at a late stage when masses are large enough to produce discomfort by invading or compressing adjacent structures. In the present case, the patient had complained of repeated abdominal distension for 3 years due to the compression of neighboring structures by the lesion. With the exception of the presence of non-islet cell tumor hypoglycemia syndrome observed in 13 cases (9,16,17,19,22,25,28,31,36,48,60,69,70), the results of laboratory tests for routine biochemical parameters, including aminotransferases or tumor markers, appear normal or slightly, non-specifically altered (33), as was the case with the present patient. Although imaging tests can provide physical characteristics of lesions for clinical analysis, including location and size, the radiological features of an SFT lack specificity, suggesting that none of the aforementioned tests are conclusive.

The gold standard for diagnosing an SFT remains as histopathological analysis combined with IHC examination. Fine-needle aspiration cytology (FNAC) is commonly performed to acquire lesion tissue for pathological diagnosis prior to surgery. Nevertheless, FNAC may be misleading or inconclusive pertaining to the diagnosis of an SFT (37). Percutaneous liver biopsy may not provide the definitive diagnosis, while increasing the risk of tumor growth and implantation (53). Histopathological findings in the present case were typical for an SFT: Diffusive proliferation of spindle-shaped mesenchymal cells with oval-fusiform nuclei along with fibrocollagenous stroma; no prominent cellular atypia, infiltrative margins or other indicative evidence of malignancy; and tumor cells of all reported cases with an SFT, including the present case, were positive for CD34, which may differentiate an SFT from other spindle cell neoplasms (12). CD99, B-cell lymphoma 2 or vimentin have also shown to be positive in almost half the cases (14–19–21,24–27,29–33,36–48,50,52–71).

Radical surgical resection is the main treatment approach. Among the reported cases listed in Table I, 85.2% (75/88) patients received radical surgical resection and on average had ≥3 segments removed owing to the size of the SFTs. Other treatments, such as chemotherapy, which was adopted recently in two patients listed in Table I, resulted in only 4–5 months survival following treatment. Therefore, Makino et al (67) suggested that due to the unclear effects of other treatments, including chemotherapy and radiotherapy, hepatic resection with clear margins is highly recommended in patients with large SFTs, considering the risk of urgent symptoms and the potential for malignancy. Compared with the previously reported cases, the tumor reported in the present study was difficult to resect using the conventional approach due to the advanced extent of the lesion therefore, novel techniques may be required.

Even with the vast improvement of surgical techniques, hepatic lesions abutting hepatic veins or the confluence of the IVC, as well as large centrally located lesions, fail to be managed by conventional surgery. In such cases, liver transplantation may be indicated (26). However, no liver transplantations have been performed to date for treating SFTs. In the present case, the second hepatic portal was compressed by the neoplasm, causing obstruction of the outflow tract and liver congestion. Full exposure of the second hepatic portal was achieved only after the sternum was removed. The vascular reconstruction and extended hepatic resection were extremely difficult to achieve by in situ surgical resection. Given the young age of the patient, the alternative of ex situ hepatectomy and liver autotransplantation was implemented. The surgery was performed successfully and the patient recovered without further complications. To the best of our knowledge, this is the first case report describing the adoption of ex situ hepatectomy and liver autotransplantation to treat a liver SFT, otherwise unresectable by standard surgery.

The ex situ hepatectomy and liver autotransplantation was initially performed by Pichlmayr et al (4) in 1988 for treating liver tumors involving major vascular structures. The procedure has progressed and developed over the past 30 years, and has been successfully applied for the treatment of several types of lesions, including hepatocellular carcinoma (72,73), hilar cholangiocarcinoma (74), giant hepatic hemangiomas (75) and metastatic colon cancer (72,73,76). The reported cases are listed in Table II. The median follow-up and survival times for these cases were 13 and 25 months, respectively. In addition, 63.6% (28/44) patients receiving ex situ hepatectomy and liver autotransplantation were <55 years old, as was the patient reported in the present case. The common indications for this method are major vein involvement and extensive resection area, both of which were noted in the present case. Compared with conventional liver resection, ex situ hepatectomy and liver autotransplantation markedly improve the rate of successful resection and clear margins of the otherwise unresectable lesions. There is no long waiting time for a suitable allograft, as an autologous liver is implanted. In addition, the total cost is lower and no post-operative immunosuppressants are required for patients receiving ex situ hepatectomy and liver autotransplantation, compared with an allograft liver transplantation (5).

Table II.

Data on reported ex situ liver autotransplantation cases.

First author, year Age, years Sex Diagnosis Characteristics of lesion/contraindication to traditional resection Follow-up (Refs.)
Pichlmayr et al, 1988 40 N/A Metastatic leiomyosarcoma Bilateral liver metastases N/A (4)
Yagyu et al, 1994 N/A N/A Intrahepatic cholangiocarcinoma Involved the confluence of the 3 main hepatic veins and the retrohepatic IVC No recurrence at 8 months (78)
Hemming and Cattral, 1999 50 M Colorectal liver metastases A single lesion in the caudate lobe involved the origin of all 3 hepatic veins N/A (76)
Lodge et al, 2000 55 F Colorectal liver metastases Involvement of IVC and segments 1, 2, 3, 4a and 8 Post-operative chemotherapy, 30 months survival (79)
Colorectal liver metastases Involvement of segments 2 and 4–8 Succumbed from complications of renal and respiratory failure on post-operative day 15
Colorectal liver metastases 17×15 cm mass involving segments 1, 2 and 4–8 Alive at 5 months
Colorectal liver metastases 17×13 cm mass involving segments 1, 2, 4–8 Alive at 5 months
Oldhafer et al, 2000 40 F Metastatic leiomyosarcoma Involvement of segments 2, 3 and 5–8 Succumbed at 36 months due to tumor recurrence (72)
46 F Metastatic colon cancer Involvement of segments 5–7 Succumbed at 13 months due to tumor recurrence
52 M Klatskin's tumor Required right hepatic trisegmentectomy Succumbed at 13 months due to tumor recurrence
58 M Metastatic colon cancer Metastatic colon cancer infiltrating the IVC Succumbed at 44 days due to sepsis and hepatic insufficiency
30 F Focal nodular hyperplasia Large FNH in segment 4 with compression Alive at 9 years of the IVC
57 M Metastatic colon cancer Infiltration of RHV requiring extended left hemihepatectomy Succumbed at 21 months due to tumor recurrence
48 F Klatskin's tumor Klatskin's tumor requiring extended left hemihepatectomy Succumbed on post-operative day 50 due to sepsis
62 M Klatskin's tumor Tumor invading left and right portal veins Succumbed on post-operative day 113 due to sepsis
55 F Klatskin's tumor Klatskin's tumor requiring right hepatic trisegmentectomy Succumbed on post-operative day 35 due to sepsis
35 M HCC HCC requiring resection of segments 1–4 Lost to follow-up and wedge 6
43 M HCC HCC requiring resection of segments 5 and 6 Succumbed at 25 months due to tumor recurrence
67 M Metastatic colon cancer Lesions requiring resection of segments 1-4b and wedge 6–7 Succumbed at 2 months due to intracerebral bleed
53 M Metastatic colon cancer Lesions requiring resection of segments 1 and 4–8 Succumbed at 2 months due to sepsis
54 F Focal nodular hyperplasia Lesions requiring resection of segments 1, 4, 5 and 7 Alive at 5 years
55 M Metastatic colon cancer Lesions requiring resection of segments 1 and 4 Succumbed at 15 months due to tumor recurrence
55 F Metastatic leiomyosarcoma Lesion requiring resection of segments 2-4b and wedge 5 Succumbed at 13 months due to tumor recurrence
52 M Metastatic colon cancer Lesions requiring resection of segments 1, 5 and 8 Succumbed at 36 months due to tumor recurrence
40 F Metastatic leiomyosarcoma Lesions requiring resection of segments 1, 4–8 and wedge 2–3 Succumbed at 18 months due to tumor recurrence
52 M Metastatic colon cancer Lesions requiring resection of segments 1 and partial 4 Succumbed on post-operative day 14 due to pneumonia
52 M Cholangiocarcinoma Lesion requiring resection of segments 1–5 and wedge 8 Succumbed on post-operative day 41 due to sepsis
39 M HCC Lesion requiring resection of segments 1–4 and partial 8 Succumbed on post-operative day 23 due to sepsis
71 M Metastatic colon cancer Lesions requiring resection of segments 1 and 5–8 Alive after 13 months
Chui et al, 2003 26 F Cholangiocarcinoma 2.3-cm hilar mass involving the portal vein confluence and right hepatic artery Alive with no recurrence on MRI at 17 months (80)
Gruttadauria et al, 2005 41 M Cholangiocarcinoma 14×12 cm mass encompassing segments 4a, 4b and 5 with RHA involvement Recurrence at 10 months and 13 months, receiving radiation; still alive at 23 months (81)
58 M Leiomyosarcoma of the IVC Third attempt at resection Discharged on post-operative day 10; long-term outcome N/A
Ikegami et al, 2007 39 F Giant hepatic hemangiomas 4 large hemangiomas in segments 1–3, caudal 4 and 6–7 Normal liver function with a regenerated liver graft at 8 months (75)
Sugimachi et al, 2010 17 F HCC 18×12 cm lesion involving IVC, RHV and first left branch of portal vein Alive 28 months after resection; no post-operative chemotherapy (82)
Gringeri et al, 2012 38 F Hepatic metastasis from 2.5 cm lesion in left lobe and 2.7-cm lesion in pancreatoblastoma Alive after 8 months right lobe involving MHV and RHV (83)
Zhang et al, 2012 60 F Hepatic hemangiomas Lesions requiring resection of segments 4–8 Alive at 22 months (74)
64 M Cholangiocarcinoma Lesions requiring resection of segments 1–4 Alive at 17 months
55 M Cholangiocarcinoma Lesions requiring resection of segments 1, 5, 7 and 8 Succumbed on post-operative day 1 due to liver and renal failure
Wen et al, 2013 67 M HCC 18×12 cm lesion at the confluence of the LHV, MHV and IVC Alive at 28 months, no recurrence (73)
71 M HCC 18×13 cm lesion at the confluence of the V7/RHV into the IVC Alive at 26 months, recurrence treated with RFA
60 M HCC 5.8×6.8 cm lesion centrally located, involving the RHV and PV Alive at 23 months, recurrence treated with TACE
Baker et al, 2015 66 F Extensive cholangiocarcinoma Lesions involving all 3 hepatic veins Alive at 3 months (6)
Vicente et al, 2017 51 M Cholangiocarcinoma Lesions involving retrohepatic vena cava together with the 3 hepatic veins Alive at 36 months (77)
Present case 32 F Solitary fibrous tumor Lesions involving the right and left hepatic arteries Alive at 3 month N/A
Open in a new tab

F, female; M, male; FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma; IVC, inferior vena cava; LHV, left hepatic vein; MHV, middle hepatic vein; PV, portal vein; RFA, radiofrequency ablation; RHV, right hepatic vein; RHA, right hepatic artery; TACE, transarterial chemoembolization; V7, hepatic vein branch draining segment VII of the liver.

The successful establishment of venous reflux and hypothermic perfusion of the isolated liver are essential for securing a successful surgery and a good prognosis (77). As the liver resection and trimming surgery are time-consuming, the prolonged anhepatic phase can lead to hemodynamic or internal environmental disturbances. Therefore, in the present case, an artificial blood vessel was used to establish an end-to-side portocaval shunt in order to maintain the venous return of the intestinal tract and lower limbs during the anhepatic period. Compared with autologous vessels, including the great saphenous vein, use of an artificial blood vessel minimizes the invasiveness of the procedure for the patient. As the shunt is temporary, the potential tissue rejection is of no concern.

The commonly encountered complications of ex situ hepatectomy and liver autotransplantation include bile leakage, bleeding, pulmonary infection, pneumonedema, hydrothorax and renal insufficiency, with a total incidence of 58.1%. The overall mortality rate within 90 days after surgery is 19.5% (5). In the present study, the patient presented with moderate right pleural effusion following surgery, and recovered fully following pleurocentesis and drainage. No other severe complications were encountered up to 3 months after surgery.

In conclusion, this is the first report that describes the successful adoption of ex situ hepatectomy and liver autotransplantation for treating an otherwise unresectable giant SFT. The uneventful surgical course and post-operative period suggested that this procedure was suitable for managing an unresectable liver neoplasm. Furthermore, the artificial blood vessels may provide a reliable source for establishing an end-to-side portocaval shunt during the anhepatic period.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant nos. 81372626 and 81572975), the Key Research and Development Project of Science and Technology Department of Zhejiang, China (grant no. 2015C03053), and the Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (2016).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SY and WW conceived and designed the study. ZS, YD, YJ, QZ, ZL, JX, JD, SY and WW performed the surgery and provided the patient care. QZ, ZL, JX and JD performed the literature review and collected the substantial data. ZS and YJ analyzed the data. ZS and YD wrote and revised the manuscript. ZS, YD and YJ organized the data and figures. SY and WW revised the final version of manuscript. All authors have read and approved the manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University.

Patient consent for publication

The patient provided written informed consent for the publication of any associated data and accompanying images.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.Salas S, Resseguier N, Blay JY, Le Cesne A, Italiano A, Chevreau C, Rosset P, Isambert N, Soulie P, Cupissol D, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: Construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28:1979–1987. doi: 10.1093/annonc/mdx250. [DOI] [PubMed] [Google Scholar]
  • 2.D'Amico FE, Ruffolo C, Romano M, DI Domenico M, Sbaraglia M, Dei Tos AP, Garofalo T, Giordano A, Bassi I, Massani M. Rare neoplasm mimicking neuoroendocrine pancreatic tumor: A case report of solitary fibrous tumor with review of the literature. Anticancer Res. 2017;37:3093–3097. doi: 10.21873/anticanres.11665. [DOI] [PubMed] [Google Scholar]
  • 3.Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control. 2006;13:264–269. doi: 10.1177/107327480601300403. [DOI] [PubMed] [Google Scholar]
  • 4.Pichlmayr R, Bretschneider HJ, Kirchner E, Ringe B, Lamesch P, Gubernatis G, Hauss J, Niehaus KJ, Kaukemüller J. Ex situ operation on the liver. A new possibility in liver surgery. Langenbecks Arch Chir. 1988;373:122–126. doi: 10.1007/BF01262775. (In German) [DOI] [PubMed] [Google Scholar]
  • 5.Tuxun T, Aini A, Li YP, Apaer S, Zhang H, Li T, Aji T, Yimiti Y, Zhao JM, Shao YM, Wen H. Systematic review of feasibility, safety and efficacy of ex situ liver resection and autotransplantation. Zhonghua Yi Xue Za Zhi. 2016;96:2251–2257. doi: 10.3760/cma.j.issn.0376-2491.2016.28.011. (In Chinese) [DOI] [PubMed] [Google Scholar]
  • 6.Baker MA, Maley WR, Needleman L, Doria C. Ex vivo resection of hepatic neoplasia and autotransplantation: A case report and review of the literature. J Gastrointest Surg. 2015;19:1169–1176. doi: 10.1007/s11605-015-2806-3. [DOI] [PubMed] [Google Scholar]
  • 7.Lehmann C, Mourra N, Tubiana JM, Arrivé L. Solitary fibrous tumor of the liver. J Radiol. 2006;87:139–142. doi: 10.1016/S0221-0363(06)73986-5. (In French) [DOI] [PubMed] [Google Scholar]
  • 8.Edmondson HA. Atlas of Tumor Pathology, Fascicle 25. Washington: Armed Forces Institute of Pathology; 1958. Tumors of the liver and intrahepatic bile ducts. [Google Scholar]
  • 9.Nevius DB, Friedman NB. Mesotheliomas and extraovarian thecomas with hypoglycaemic and nephritic syndromes. Cancer. 1959;12:1263–1269. doi: 10.1002/1097-0142(195911/12)12:6&#x0003c;1263::AID-CNCR2820120620&#x0003e;3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  • 10.Ishak KG. Mesenchymal tumors of the liver. In: Okusa K, Peters RL, editors. Hepatocellular Carcinoma. John Wiley and Sons; New York, USA: 1976. pp. 247–307. [Google Scholar]
  • 11.Kim H, Damjanov I. Localised fibrous mesothelioma of the liver. Report of a giant tumour studied by light and electron microscopy. Cancer. 1983;52:1662–1665. doi: 10.1002/1097-0142(19831101)52:9&#x0003c;1662::AID-CNCR2820520919&#x0003e;3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 12.Kottke-Marchant K, Hart WR, Broughan T. Localized fibrous tumor (localized fibrous mesothelioma) of the liver. Cancer. 1989;64:1096–1102. doi: 10.1002/1097-0142(19890901)64:5&#x0003c;1096::AID-CNCR2820640521&#x0003e;3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  • 13.Kasano Y, Tanimura H, Tabuse K, Nagai Y, Mori K, Minami K. Giant fibrous mesothelioma of the liver. Am J Gastroenterol. 1991;86:379–380. [PubMed] [Google Scholar]
  • 14.Barnoud R, Arvieux C, Pasquier D, Pasquier B, Letoublon C. Solitary fibrous tumour of the liver with CD34 expression. Histopathology. 1996;28:551–554. doi: 10.1046/j.1365-2559.1996.d01-468.x. [DOI] [PubMed] [Google Scholar]
  • 15.Levine TS, Rose DS. Solitary fibrous tumour of the liver. Histopathology. 1997;30:396–397. [PubMed] [Google Scholar]
  • 16.Guglielmi A, Frameglia M, Iuzzolino P, Iuzzolino P, Martignoni G, De Manzoni G, Laterza E, Veraldi GF, Girlanda R. Solitary fibrous tumor of the liver with CD 34 positivity and hypoglycaemia. J Hepatobiliary Pancreat Surg. 1998;5:212–216. doi: 10.1007/s005340050036. [DOI] [PubMed] [Google Scholar]
  • 17.Lecesne R, Drouillard J, Le Bail B, Saric J, Balabaud C, Laurent F. Localised fibrous tumor of the liver: Imaging findings. Eur Radiol. 1998;8:36–38. doi: 10.1007/s003300050333. [DOI] [PubMed] [Google Scholar]
  • 18.Bejarano PA, Blanco R, Hanto DW. Solitary fibrous tumor of the liver. A case report, river of the literature and differential diagnosis of spindle cell lesions of the liver. Int J Surg Pathol. 1998;6:93–100. doi: 10.1177/106689699800600206. [DOI] [Google Scholar]
  • 19.Moran CA, Ishak KG, Goodman ZD. Solitary fibrous tumor of the liver: A clinicopathologic and immunohistochemical study of nine cases. Ann Diagn Pathol. 1998;2:19–24. doi: 10.1016/S1092-9134(98)80031-2. [DOI] [PubMed] [Google Scholar]
  • 20.Fuksbrumer MS, Klaimstra D, Panicek DM. Solitary fibrous tumor of the liver: Imaging findings. AJR Am J Roentgenol. 2000;175:1683–1687. doi: 10.2214/ajr.175.6.1751683. [DOI] [PubMed] [Google Scholar]
  • 21.Yilmaz S, Kirimlioglu V, Ertas E, Hilmioglu F, Yildirim B, Katz D, Mizrak B. Giant solitary fibrous tumor of the liver with metastasis to the skeletal system successfully treated with trisegmentectomy. Dig Dis Sci. 2000;45:168–174. doi: 10.1023/A:1005569128877. [DOI] [PubMed] [Google Scholar]
  • 22.Lin YT, Lo GH, Lai KH, Tsai CC, Pan HB, Tseng HH, Lo YS. Solitary fibrous tumor of the liver. Zhonghua Yi Xue Za Zhi (Taipei) 2001;64:305–309. [PubMed] [Google Scholar]
  • 23.Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ, Brennan MF, Coit DG. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94:1057–1068. doi: 10.1002/cncr.10328. [DOI] [PubMed] [Google Scholar]
  • 24.Neeff H, Obermaier R, Technau-Ihling K, Werner M, Kurtz C, Imdahl A, Hopt UT. Solitary fibrous tumour of the liver: Case report and review of the literature. Langenbecks Arch Surg. 2004;389:293–298. doi: 10.1007/s00423-004-0488-5. [DOI] [PubMed] [Google Scholar]
  • 25.Chithriki M, Jaibaji M, Vandermolen R. Solitary fibrous tumor of the liver with presening symptoms of hypoglycemic coma. Am Surg. 2004;70:291–293. [PubMed] [Google Scholar]
  • 26.Vennarecci G, Ettorre GM, Giovannelli L, Del Nonno F, Perracchio L, Visca P, Corazza V, Vidiri A, Visco G, Santoro E. Solitary fibrous tumor of the liver. J Hepatobiliary Pancreat Surg. 2005;12:341–344. doi: 10.1007/s00534-005-0993-0. [DOI] [PubMed] [Google Scholar]
  • 27.Moser T, Nogueira TS, Neuville A, Riehm S, Averous G, Weber JC, Veillon F. Delayed enhancement pattern in a localised fibrous tumor of the liver. AJR Am J Roentgenol. 2005;184:1578–1580. doi: 10.2214/ajr.184.5.01841578. [DOI] [PubMed] [Google Scholar]
  • 28.Ji Y, Fan J, Xu Y, Zhou J, Zeng HY, Tan YS. Solitary fibrous tumor of the liver. Hepatobiliary Pancreat Dis Int. 2006;5:151–153. [PubMed] [Google Scholar]
  • 29.Nath DS, Rutzick AD, Sielaff TD. Solitary fibrous tumor of the liver. AJR Am J Roentgenol. 2006;187:187–190. doi: 10.2214/AJR.05.0294. [DOI] [PubMed] [Google Scholar]
  • 30.Terkivatan T, Kliffen M, de Wilt JH, van Geel AN, Eggermont AM, Verhoef C. Giant solitary fibrous tumour of the liver. World J Surg Oncol. 2006;4:81. doi: 10.1186/1477-7819-4-81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Chan G, Horton PJ, Thyssen S, Lamarche M, Nahal A, Hill DJ, Marliss EB, Metrakos P. Malignant transformation of a solitary fibrous tumor of the liver and intractable hypoglycaemia. J Hepatobiliary Pancreat Surg. 2007;14:595–599. doi: 10.1007/s00534-007-1210-0. [DOI] [PubMed] [Google Scholar]
  • 32.Obuz F, Secil M, Sagol O, Karademir S, Topalak O. Ultrasonography and magnetic resonance imaging findings of solitary fibrous tumor of the liver. Tumori. 2007;93:100–102. doi: 10.1177/030089160709300118. [DOI] [PubMed] [Google Scholar]
  • 33.Perini MV, Herman P, D'Albuquerque LA, Saad WA. Solitary fibrous tumor of the liver: Report of a rare case and review of the literature. Int J Surg. 2008;6:396–399. doi: 10.1016/j.ijsu.2007.10.004. [DOI] [PubMed] [Google Scholar]
  • 34.Weitz J, Klimstra DS, Cymes K, Jarnagin WR, D'Angelica M, La Quaglia MP, Fong Y, Brennan MF, Blumgart LH, Dematteo RP. Management of primary liver sarcomas. Cancer. 2007;109:1391–1396. doi: 10.1002/cncr.22530. [DOI] [PubMed] [Google Scholar]
  • 35.Kandpal H, Sharma R, Gupta SD, Kumar A. Solitary fibrous tumour of the liver: A rare imaging diagnosis using MRI and diffusion-weighted imaging. Br J Radiol. 2008;81:e282–e286. doi: 10.1259/bjr/98393711. [DOI] [PubMed] [Google Scholar]
  • 36.Famà F, Le Bouc Y, Barrande G, Villeneuve A, Berry MG, Pidoto RR, Marc Saint O. Solitary fibrous tumour of the liver with IGF-II-related hypoglycaemia. A case report. Langenbecks Arch Surg. 2008;393:611–616. doi: 10.1007/s00423-008-0329-z. [DOI] [PubMed] [Google Scholar]
  • 37.Korkolis DP, Apostolaki K, Aggeli C, Plataniotis G, Gontikakis E, Volanaki D, Sebastiadou M, Dimitroulopoulos D, Xinopoulos D, Zografos GN, Vassilopoulos PP. Solitary fibrous tumor of the liver expressing CD34 and vimentin: A case report. World J Gastroenterol. 2008;14:6261–6264. doi: 10.3748/wjg.14.6261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chen JJ, Ong SL, Richards C, Garcea G, Pollard C, Berry D, Dennison A. Inaccuracy of fine-needle biopsy in the diagnosis of solitary fibrous tumour of the liver. Asian J Surg. 2008;31:195–198. doi: 10.1016/S1015-9584(08)60085-8. [DOI] [PubMed] [Google Scholar]
  • 39.El-Khouli RH, Geschwind JF, Bluemke DA, Kamel IR. Solitary fibrous tumor of the liver: Magnetic resonance imaging evaluation and treatment with transarterial chemoembolisation. J Comput Assist Tomogr. 2008;32:769–771. doi: 10.1097/RCT.0b013e3181557453. [DOI] [PubMed] [Google Scholar]
  • 40.Hoshino M, Nakajima S, Futagawa Y, Fujioka S, Okamoto T, Yanaga K. A solitary fibrous tumor originating from the liver surface. Clin J Gastroenterol. 2009;2:320–324. doi: 10.1007/s12328-009-0097-5. [DOI] [PubMed] [Google Scholar]
  • 41.Novais P, Robles-Medranda C, Pannain VL, Barbosa D, Biccas B, Fogaca H. Solitary fibrous liver tumor: Is surgical approach the best option? J Gastrointestin Liver Dis. 2010;19:81–84. [PubMed] [Google Scholar]
  • 42.Brochard C, Michalak S, Aubé C, Singeorzan C, Fournier HD, Laccourreye L, Calès P, Boursier J. A not so solitary fibrous tumor of the liver. Gastroenterol Clin Biol. 2010;34:716–720. doi: 10.1016/j.gcb.2010.08.004. [DOI] [PubMed] [Google Scholar]
  • 43.Haddad A, Karras R, Fraiman M, Mackey R. Solitary fibrous tumor of the liver. Am Surg. 2010;76:E78–E79. [PubMed] [Google Scholar]
  • 44.Park HS, Kim YK, Cho BH, Moon WS. Pedunculated hepatic mass. Liver Int. 2011;31:541. doi: 10.1111/j.1478-3231.2010.02318.x. [DOI] [PubMed] [Google Scholar]
  • 45.Peng L, Liu Y, Ai Y, Liu Z, He Y, Liu Q. Skull base metastases from a malignant solitary fibrous tumor of the liver. A case report and literature review. Diagn Pathol. 2011;6:127. doi: 10.1186/1746-1596-6-127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Sun K, Lu JJ, Teng XD, Ying LX, Wei JF. Solitary fibrous tumor of the liver: A case report. World J Surg Oncol. 2011;9:37. doi: 10.1186/1477-7819-9-37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Patra S, Vij M, Venugopal K, Rela M. Hepatic solitary fibrous tumor: A report of a rare case. Indian J Pathol Microbiol. 2012;55:236–238. doi: 10.4103/0377-4929.97892. [DOI] [PubMed] [Google Scholar]
  • 48.Radunz S, Baba HA, Sotiropoulos GC. Large tumor of the liver and hypoglycemic shock in an 85-year-old patient. Gastroenterology. 2012;142:e10–e11. doi: 10.1053/j.gastro.2011.02.072. [DOI] [PubMed] [Google Scholar]
  • 49.Belga S, Ferreira S, Lemos MM. A rare tumor of the liver with a sudden presentation. Gastroenterology. 2012;143:e14–e15. doi: 10.1053/j.gastro.2012.02.045. [DOI] [PubMed] [Google Scholar]
  • 50.Morris R, McIntosh D, Helling T, Martin JN., Jr Solid fibrous tumor of the liver: A case in pregnancy. J Matern Fetal Neonatal Med. 2012;25:866–868. doi: 10.3109/14767058.2011.596958. [DOI] [PubMed] [Google Scholar]
  • 51.Beyer L, Delpero JR, Chetaille B, Sarran A, Perrot D, Moureau-Zabotto L, Guiramand J, Bertucci F. Solitary fibrous tumor in the round ligament of the liver: A fortunate intraoperative discovery. Case Rep Oncol. 2012;5:187–194. doi: 10.1159/000338616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Soussan M, Felden A, Cyrta J, Morère JF, Douard R, Wind P. Case 198: Solitary fibrous tumor of the liver. Radiology. 2013;269:304–308. doi: 10.1148/radiol.13121315. [DOI] [PubMed] [Google Scholar]
  • 53.Liu Q, Liu J, Chen W, Mao S, Guo Y. Primary solitary fibrous tumors of liver: A case report and literature review. Diagn Pathol. 2013;8:195. doi: 10.1186/1746-1596-8-195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Jakob M, Schneider M, Hoeller I, Laffer U, Kaderli R. Malignant solitary fibrous tumor involving the liver. World J Gastroenterol. 2013;19:3354–3357. doi: 10.3748/wjg.v19.i21.3354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Debs T, Kassir R, Amor IB, Martini F, Iannelli A, Gugenheim J. Solitary fibrous tumor of the liver: Report of two cases and review of the literature. Int J Surg. 2014;12:1291–1294. doi: 10.1016/j.ijsu.2014.10.037. [DOI] [PubMed] [Google Scholar]
  • 56.Durak Güray M, Sağol Ö, Tuna B, Ertener Ö, Ünek T, Karademır S, Dıcle O. Cystic solitary fibrous tumor of the liver: A case report. Turk Patoloji Derg. 2013;29:217–220. doi: 10.5146/tjpath.2013.01173. [DOI] [PubMed] [Google Scholar]
  • 57.Vythianathan M, Yong J. A rare primary malignant solitary fibrous tumour of the liver. Pathology. 2013;45:86–87. doi: 10.1097/01.PAT.0000426954.68370.26. [DOI] [Google Scholar]
  • 58.Song L, Zhang W, Zhang Y. (18)F-FDG PET/CT imaging of malignant hepatic solitary fibrous tumor. Clin Nucl Med. 2014;39:662–664. doi: 10.1097/RLU.0000000000000431. [DOI] [PubMed] [Google Scholar]
  • 59.Teixeira F, Jr, de Freitas Perina AL, de Oliveira Mendes G, de Andrade AB, da Costa FP. Fibrous solitary tumour of the liver. J Gastrointest Canc. 2014;45(Suppl 1):S216–S217. doi: 10.1007/s12029-014-9635-6. [DOI] [PubMed] [Google Scholar]
  • 60.Du EH, Walshe TM, Buckley AR. Recurring rare liver tumor presenting with hypoglycemia. Gastroenteroloy. 2015;148:e11–e13. doi: 10.1053/j.gastro.2014.09.036. [DOI] [PubMed] [Google Scholar]
  • 61.Beltrán MA. Solitary fibrous tumor of the liver: A review of the current knowledge and report of a new case. J Gastrointest Canc. 2015;46:333–342. doi: 10.1007/s12029-015-9769-1. [DOI] [PubMed] [Google Scholar]
  • 62.Bejarano-Gonzalez N, Garcia-Borobia FJ, Romaguera-Monzonis A, García-Monforte N, Falcó-Fagés J, Bella-Cueto MR, Navarro-Soto S. Soliary fibrous tumor of the liver. Case report and review of the literature. Rev Esp Enferm Dig. 2015;107:633–639. doi: 10.17235/reed.2015.3676/2014. [DOI] [PubMed] [Google Scholar]
  • 63.Feng LH, Dong H, Zhu YY, Cong WM. An update on primary hepatic solitary fibrous tumor: An examination of the clinical and pathological features of four case studies and a literature review. Pathol Res Pract. 2015;211:911–917. doi: 10.1016/j.prp.2015.09.004. [DOI] [PubMed] [Google Scholar]
  • 64.Silvanto A, Karanjia ND, Bagwan IN. Primary hepatic solitary fibrous tumor with histologically benign and malignant areas. Hepatobiliary Pancreat Dis Int. 2015;14:665–668. doi: 10.1016/S1499-3872(15)60365-4. [DOI] [PubMed] [Google Scholar]
  • 65.Kueht M, Masand P, Rana A, Cotton R, Goss J. Concurrent hepatic hemangioma and solitary fibrous tumor: Diagnosis and management. J Surg Case Rep. 2015;2015:rjv089. doi: 10.1093/jscr/rjv089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Maccio L, Bonetti LR, Siopis E, Palmiere C. Malignant metastasizing solitary fibrous tumors of the liver: A report of three cases. Pol J Pathol. 2015;66:72–76. doi: 10.5114/pjp.2015.51156. [DOI] [PubMed] [Google Scholar]
  • 67.Makino Y, Miyazaki M, Shigekawa M, Ezaki H, Sakamori R, Yakushijin T, Ohkawa K, Kato M, Akasaka T, Shinzaki S, et al. Solitary fibrous tumor of the liver from development to resection. Intern Med. 2015;54:765–770. doi: 10.2169/internalmedicine.54.3053. [DOI] [PubMed] [Google Scholar]
  • 68.Dey B, Gochhait D, Kaushal G, Barwad A, Pottakkat B. Solitary fibrous tumor of the liver: A rare tumor in a rarer location. Rare Tumors. 2016;8:6403. doi: 10.4081/rt.2016.6403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Degnan AJ, Lee KK, Minervini MI, Borhani AA. Metastatic extrapleural malignant solitary fibrous tumor presenting with hypoglycemia (Doege-Potter syndrome) Radiol Case Rep. 2016;12:113–119. doi: 10.1016/j.radcr.2016.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Mačák J, Buzrla P, Dvořáčková J, Prokop P, Jalůvka F. Hypoglycemia in a solitary fibrous tumor of the liver. Cesk Patol. 2016;52:41–44. (In Czech) [PubMed] [Google Scholar]
  • 71.Chen N, Slater K. Solitary fibrous tumour of the liver-report on metastasis and local recurrence of a malignant case and review of literature. World J Surg Oncol. 2017;15:27. doi: 10.1186/s12957-017-1102-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Oldhafer KJ, Lang H, Schlitt HJ, Hauss J, Raab R, Klempnauer J, Pichlmayr R. Long-term experience after ex situ liver surgery. Surgery. 2000;127:520–527. doi: 10.1067/msy.2000.105500. [DOI] [PubMed] [Google Scholar]
  • 73.Wen PH, Lin KH, Chen YL, Hsieh CE, Ko CJ, Kuo SJ. Extracorporeal hepatic resection and autotransplantation using temporary portocaval shunt provides an improved solution for conventionally unresectable HCC. Dig Dis Sci. 2013;58:3637–3640. doi: 10.1007/s10620-013-2801-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Zhang KM, Hu XW, Dong JH, Hong ZX, Wang ZH, Li GH, Qi RZ, Duan WD, Zhang SG. Ex-situ liver surgery without veno-venous bypass. World J Gastroenterol. 2012;18:7290–7295. doi: 10.3748/wjg.v18.i48.7290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Ikegami T, Soejima Y, Taketomi A, Kayashima H, Sanefuji K, Yoshizumi T, Harada N, Yamashita Y, Maehara Y. Extracorporeal hepatic resection for unresectable giant hepatic hemangiomas. Liver Transpl. 2008;14:115–117. doi: 10.1002/lt.21272. [DOI] [PubMed] [Google Scholar]
  • 76.Hemming AW, Cattral MS. Ex vivo liver resection with replacement of the inferior vena cava and hepatic vein replacement by transposition of the portal vein. J Am Coll Surg. 1999;189:523–526. doi: 10.1016/S1072-7515(99)00192-1. [DOI] [PubMed] [Google Scholar]
  • 77.Vicente E, Quijano Y, Ielpo B, Duran H, Diaz E, Fabra I, Malavé L, Ferri V, Lazzaro S, Kalivaci D, Caruso R. Ex Situ Hepatectomy and Liver Autotransplantation for Cholangiocarcinoma. Ann Surg Oncol. 2017;24:3990. doi: 10.1245/s10434-017-6104-z. [DOI] [PubMed] [Google Scholar]
  • 78.Yagyu T, Shimizu R, Nishida M, Nakashima K, Uchiyama T, Suzuki T. Reconstruction of the hepatic vein to the prosthetic inferior vena cava in right extended hemihepatectomy with ex situ procedure. Surgery. 1994;115:740–744. [PubMed] [Google Scholar]
  • 79.Lodge JP, Ammori BJ, Prasad KR, Bellamy MC. Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. Ann Surg. 2000;231:471–479. doi: 10.1097/00000658-200004000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Chui AK, Rao AR, Wong J, Mann D, Leung KF, Lau WY. Ex Situ Ex Vivo liver resection, partial liver autotransplantation for advanced Hilar cholangiocarcinoma: A case report. Transplant Proc. 2003;35:402–403. doi: 10.1016/S0041-1345(02)03774-0. [DOI] [PubMed] [Google Scholar]
  • 81.Gruttadauria S, Marsh JW, Bartlett DL, Gridelli B, Marcos A. Ex Situ resection techniques and liver autotransplantation: Last resource for otherwise unresectable malignancy. Dig Dis Sci. 2005;50:1829–1835. doi: 10.1007/s10620-005-2946-5. [DOI] [PubMed] [Google Scholar]
  • 82.Sugimachi K, Shirabe K, Taketomi A, Soejima Y, Yoshizumi T, Yamashita Y, Umeda K, Morita K, Maehara Y. Successful curative extracorporeal hepatic resection for far-advanced hepatocellular carcinoma in an adolescent patient. Liver Transpl. 2010;16:685–687. doi: 10.1002/lt.22051. [DOI] [PubMed] [Google Scholar]
  • 83.Gringeri E, Polacco M, D'Amico FE, Bassi D, Boetto R, Tuci F, Bonsignore P, Noaro G, D'Amico F, Vitale A, et al. Liver autotransplantation for the treatment of unresectable hepatic metastasis: An uncommon indication-a case report. Transplant Proc. 2012;44:1930–1933. doi: 10.1016/j.transproceed.2012.06.032. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES